DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI — Stella

Recruiting

Back to Esophageal Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment target

~120 participants

Started

August 2025

Primary completion

August 2027

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov